Abstract

Development of a cytomegalovirus (CMV) vaccine is a major public health priority due to the risk of congenital infection. A key component of a vaccine is thought to be an effective neutralizing antibody response against the viral glycoproteins necessary for cell entry. Species specificity of human CMV (HCMV) precludes direct studies in an animal model. The guinea pig is the only small animal model for congenital cytomegalovirus infection. Analysis of the guinea pig CMV (GPCMV) genome indicates that it potentially encodes homologs to the HCMV glycoproteins (including gB, gH, gL, gM, gN and gO) that form various cell entry complexes on the outside of the virus: gCI (gB); gCII (gH/gL/gO); gCIII (gM/gN). The gB homolog (GP55) has been investigated as a candidate subunit vaccine but little is known about the other homolog proteins. GPCMV glycoproteins were investigated by transient expression studies which indicated that homolog glycoproteins to gN and gM, or gH, gL and gO were able to co-localize in cells and generate respective homolog complexes which could be verified by immunoprecipitation assays. ELISA studies demonstrated that the individual complexes were highly immunogenic in guinea pigs. The gO (GP74) homolog protein has 13 conserved N-glycosylation sites found in HCMV gO. In transient expression studies, only the glycosylated protein is detected but in virus infected cells both N-glycosylated and non-glycosylated gO protein were detected. In protein interaction studies, a mutant gO that lacked N-glycosylation sites had no impact on the ability of the protein to interact with gH/gL which indicated a potential alternative function associated with these sites. Knockout GPCMV BAC mutagenesis of the respective glycoprotein genes (GP55 for gB, GP75 for gH, GP115 for gL, GP100 for gM, GP73 for gN and GP74 for gO) in separate reactions was lethal for virus regeneration on fibroblast cells which demonstrated the essential nature of the GPCMV glycoproteins. The gene knockout results were similar to HCMV, except in the case of the gO homolog, which was non-essential in epithelial tropic virus but essential in lab adapted GPCMV. Overall, the findings demonstrate the similarity between HCMV and GPCMV glycoproteins and strengthen the relevance of this model for development of CMV intervention strategies.

Highlights

  • Congenital human cytomegalovirus (HCMV) infection occurs in approximately 1% of live births in the US and can lead to symptomatic disease including mental retardation and hearing loss [1, 2]

  • We investigated the immunogenicity of these complexes using convalescent sera from guinea pig CMV (GPCMV) infected guinea pigs and newly established ELISA assays to various glycoprotein complexes

  • GPCMV, first and second generation GPCMV BAC [20, 21] derived viruses were propagated on guinea pig fibroblast lung cells (GPL; ATCC CCL 158) in F-12 medium supplemented with 10% fetal calf serum (FCS, Life Technologies), 10,000 IU of penicillin/liter, 10 mg of streptomycin/liter (Gibco-BRL), and 7.5% NaHCO3 (Gibco-BRL)

Read more

Summary

Introduction

Congenital human cytomegalovirus (HCMV) infection occurs in approximately 1% of live births in the US and can lead to symptomatic disease including mental retardation and hearing loss [1, 2]. In congenital HCMV infection, the greatest risk is to mothers who acquire a primary infection during pregnancy [3], with an overall fetal transmission rate of 37.1% to 64.1% [4]. It is realistic to expect that a vaccine against HCMV will offer some form of protection against congenital infection since vertical transmission is relatively low in mothers convalescent for HCMV. With an estimated level of transmission to sero-negative pregnant women of 27,000 per year in the US [5] the impact of a vaccine could be substantial in reducing the risk for congenital CMV infection. Any proposed intervention therapy for the prevention or treatment of HCMV infection should ideally be evaluated in an animal model. Due to the extreme species specificity of HCMV, studies in animal models are untenable

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call